1. A study protocol for a multi-country cluster randomized controlled trial of the impact of a multi-component One Health strategy to eliminate Opisthorchis viverrini and soil transmitted helminths in the Lower Mekong Basin.
- Author
-
Mationg ML, Clements ACA, Williams GM, Kelly M, Stewart DE, Gordon CA, Wangdi K, Tangkawattana S, Suwannatrai AT, Savathdy V, Khieu V, Wannachart S, O'Connor SY, Forsyth S, Gannon S, Odermatt P, McManus DP, Sayasone S, Khieu V, Sripa B, and Gray DJ
- Subjects
- Humans, Animals, One Health, Thailand epidemiology, Cambodia epidemiology, Laos, Child, Multicenter Studies as Topic, Adolescent, Adult, Female, Male, Treatment Outcome, Mass Drug Administration methods, Young Adult, Middle Aged, Health Promotion methods, Opisthorchiasis prevention & control, Opisthorchiasis parasitology, Opisthorchiasis epidemiology, Praziquantel therapeutic use, Opisthorchis, Anthelmintics therapeutic use, Albendazole therapeutic use, Soil parasitology, Randomized Controlled Trials as Topic, Helminthiasis prevention & control, Helminthiasis transmission, Helminthiasis epidemiology, Helminthiasis drug therapy, Helminthiasis parasitology
- Abstract
Background: Opisthorchis viverrini (OV) and soil-transmitted helminths (STH) are two of the most common helminths contributing to the Neglected Tropical Disease (NTDs) burden in the Lower Mekong Basin. Although mass drug administration is the cornerstone of control programs to reduce morbidity caused by these infections, this approach has limitations in preventing re-infections. Elimination requires additional measures such as reservoir host treatment, improved hygiene and health education to reinforce MDA's impact. This study aims to examine the impact of a scalable multi-component One Health Helminth Elimination program in the Lower Mekong Basin (HELM) that combines human praziquantel (PZQ) and albendazole (ALB) treatment with a program that includes the "Magic Glasses" and the "Lawa Model" interventions with health promotion at their core., Methods: This study will employ a cluster randomized controlled trial (cRCT) in 18 rural communities (with sub-district or villages as cluster units) across Cambodia, Laos and Thailand. The control arm will receive one round of PZQ/ALB treatment, while in the intervention arm, multi-component HELM program will be implemented, which includes PZQ/ALB treatment together with the Magic Glasses and Lawa Model interventions. OV and STH infections levels will be evaluated in individuals aged 5-75 years at baseline and will be repeated at follow-up (12 months after the HELM intervention), using modified formalin ethyl-acetate concentration technique and quantitative PCR. The primary outcome of the study will be cumulative incidence of human OV and STH infections. Outcomes between the study arms will be compared using generalized linear mixed models, accounting for clustering., Discussion: Evidence from this trial will quantify the impact of a multi-component One Health control strategy in interrupting Ov and STH infections in the Lower Mekong Basin., Trial Registration: Australian New Zealand Clinical Trials Registry (ANZCTR): ACTRN12622000353796. Prospectively registered 28 February 2022., Competing Interests: Declarations. Ethics approval and consent to participate: This study was submitted to and received ethical approval from the Australian National University Human Research Ethics Committee (Protocol number 2022/507), Cambodia Ministry of Health National Ethics Committee for Health Research (NECHR) (209NECHR), the Lao PDR Ministry NECHR (07NCEHR) and Khon Kaen University Ethics Committee for Human Research (Reference No. HE651147). This study is prospectively registered with the Australian New Zealand Clinical Trials Registry (ANZCTR): ACTRN12622000353796. Participation in the survey will be voluntary. Informed consent will be obtained from all participants ≥ 18 years old. Inclusion of participants < 18 years old required consent from a parent or guardian and assent from individuals 5 to 17 years old. The study objectives, intervention components, voluntary participation and the right to withdraw at any time will be verbally elaborated and outlined in the information sheet. Two copies will be signed by the study participants: an original copy and a duplicate. Researchers will keep the original copies of the consents signed by the study participants and leave the duplicate copies with them for their own records. This trial will also involve collection of stool specimens for storage. If the study participants will not allow the storage and use of remaining stool samples for future research, the remaining samples will be disposed immediately after the completion of all the procedures of this study. This study also obtained ethical approval from the Australian National University Animal Ethics Committee (Protocol Number A2022/27) and Institutional Animal Care and Use Committee of Khon Kaen University (Reference No. 660201.2.11/245 (39)). Consent for publication: Not applicable—there are no personal information or identifying images of study participants are presented here or will be presented in reports of the trial results. Competing interests: The authors declare that they have no competing interests., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF